9 news items
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
(GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY
25 Apr 24
of Abecma in Earlier-Line Multiple Myeloma and Breyanzi in Chronic
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
BMY
25 Mar 24
agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial
Bristol Myers' Breyanzi Scores Second FDA Approval For Blood Cancers Therapy
BMY
15 Mar 24
receptor (CAR) T cell therapy, for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The approval covers
pcjret08qbvr29
BMY
15 Mar 24
qfdeytrn
BMY
14 Mar 24
chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine
j28lz2yxots28p6j
BMY
7 Mar 24
), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without
x4ym1oqgh4ycvc1yis62mr72du4 p54hxmuyhi9c4
BMY
IMCR
28 Feb 24
after stopping medication for people living with chronic HBV. About ImmTAAI molecules and autoimmune diseases
- Prev
- 1
- Next